The selection of the best candidates for surgery among Parkinson's disease (PD) patients is a debated topic. This could be particularly important for transplantation studies in which patients with advanced PD and motor complications refractory to conventional pharmacological treatments are usually included. The development of lesions in nondopaminergic structures, which apparently are unaffected by the intervention, could eventually lead to the appearance of disabling, treatment-resistant symptoms. This has been considered as the crucial factor responsible for the outcome of any therapeutic procedure. However, other factors might be involved. It is suggested in this article that the rate of progression of PD and the effects of ageing are more important than the extradopaminergic involvement in the final outcome. Rate of progression of PD is critically related to the power of compensatory mechanisms, which are age related and under the control of still unknown genes. Thus, patients with young onset parkinsonism (YOP), either caused by gene mutations or not, could be the best candidates for surgery because they have a slower disease progression and more competent compensatory mechanisms. On the other hand, this can also explain the appearance of unexpected side effects such as the "runaway" dyskinesias reported following transplantation.
INTRODUCTION
ventional pharmacological treatments. However, in advanced disease it is not optimal in terms of successful neural transplantation. This article briefly reviews data Current surgical therapies for Parkinson's disease (PD) include ablative treatment, deep brain stimulation (DBS), that lend support to the hypothesis that the rate of progression of PD and the effects of ageing, rather than the and transplantation procedures [for a review see (3, 65) ]. Among transplantation procedures, fetal nigral trans-involvement of nondopaminergic nuclei in the disease process, are the key elements responsible for the long-plants into the striatum are the most studied (5, 21, 27, 29, 43, 49) . Considerably less experience exists for other term response to any therapy. In keeping with this idea, patients with young onset parkinsonism (YOP), caused approaches [carotid body cell transplantation (2), retinal cell transplantation (67) , as well as infusion of GDNF by gene mutations or not, could be the best candidates for surgery because they have a slower disease progres-directly in the striatum (24) ]; thus, they will not be discussed here although comparable conclusions could be sion and more competent compensatory mechanisms. drawn.
TRANSPLANTATION The selection of the best candidates for surgery is a OF FETAL DOPAMINERGIC CELLS: debated topic. Because the approaches outline above are THE CURRENT SITUATION associated with risks inherent to any brain surgical intervention, they are usually indicated for patients with After extensive studies in animal models demonstrating proof of principle (survival of implanted cells pro-advanced PD and motor complications refractory to con-464 LINAZASORO viding improvement of motor deficits without serious ad-which might be determinant in the outcome (see below, Table 2 and Figs. 1 and 2) . Furthermore, the clinical verse effects), transplantation of fetal dopaminergic cells to parkinsonian patients was started in the late 1980s (5, outcome was better in patients younger than 60 in one study (21) and in patients with a lower disease severity 27, 29, 43) . Initial small open label studies showed clinical results that were congruent with animal experiments:
(UPDRS III score below 49) in another (49). In these particular groups, clinical improvement was significant it was a safe procedure and patients experienced clinical benefits of variable degree that were correlated with cell ( p < 0.005). These data lend support to the central argument of the hypothesis proposed here (see below). To survival according to PET and pathological studies (5, 27, 29, 43, 52, 53) . Importantly, the demonstration of a late add confusion to this complex scenario, a more recent evaluation of the first study using objective quantitative normalization of neuronal activity in premotor cortical areas by performing PET activation studies strongly sug-measures (reaction time and movement time) has shown significant improvement in motor function, suggesting gested a logical sequence of events relating survival, integration, and functioning of implanted cells with mo-that comprehensive analyses of a range of neurophysiological measures may reveal subtle changes in motor toric improvement (52, 53) . Hence, the benefits were progressive and long lasting, supporting the hypothesis performance across time (25, 56) . Currently, transplantation approaches are experimen-that the mechanism of action of fetal nigral transplants relies upon a reestablishment of appropriate synaptic tal and limited to a few centers around the world. In the studies to date, patients with advanced, levodopa-connections in the striatum between implanted and host cells, which is a slow and continuous process. However, responsive PD resistant to medical therapies and with severe off-periods have been included. As tremor and results from two double-blind placebo-controlled studies challenged this prior experience (21, 49) . In brief, these dyskinesias were not significantly improved in early studies, patients with severe forms of both symptoms studies failed to show meaningful clinical amelioration after transplantation in spite of significant increases in have been excluded. Cognitive function and brain MRI should be normal and no general contraindications for striatal fluorodopa uptake in PET scans. In addition, quite unexpectedly, a considerable proportion of patients surgery should be present. In general terms, results of double-blind studies (21,49) emphasize the need for fur-developed dyskinesias.
A critical review of these and other transplantation ther studies in animal models of parkinsonism with dyskinesias. Furthermore, selection criteria, as well as other studies has been published, and several shortcomings that might explain the overall poor outcome have been methodological issues, should be continually reviewed and modified, as appropriate. identified (68). Among them, preparation and composition of the graft and its placement in the striatum, as
The main objective of cell therapy should not be limited to replacing the dopamine deficiency but should be well as immune problems leading to a partial and irregular reinnervation of the putamen, received special atten-directed at restoring or reestablishing the normal anatomy (connectivity) and physiology (appropriate synaptic tion (68). Nevertheless, other factors, such as the selection of the most appropriate recipients, might also be of contacts and functioning) of the striatum (6, 23, 27) . This is not easy because cells are ectopically placed, their great importance (68) and need to be emphasized. Thus, careful analysis of the Olanow et al. study (49) shows survival is quite low, and reestablishing physiological connections in a denervated and nonphysiologically that age at onset and duration of PD were quite different among the three subgroups studied (Table 1) . This fact treated striatum is a complex task (6,23). Nevertheless, the creation of a new balanced situation could be enough may be important because the severity of PD as assessed by the motor UPDRS was comparable, thus suggesting and should be actively pursued. The potential neuroprotective role of gene therapy and the local application of different rates of progression between the three groups, trophic factors is beyond the scope of this review, although cell-based therapies could critically contribute to their achievement. ing paragraphs.
INFLUENCE OF AGEING IN PD
symptoms begin, suggesting a very long preclinical period and very powerful compensatory mechanisms (9, Ageing may influence the clinical course of PD, main- 32, 35, 55, 59, 62) . Alternatively, Calne and Mizuno (10) ly by three mechanisms: 1) effects on compensatory mechsuggested that the differences in the clinical course beanisms, 2) normal loss of neurons; 3) associated patholotween YOP patients and patients with IPD starting at gies. more advanced ages relates to the greater number of Effects on Compensatory Mechanisms nigral dopaminergic neurons in YOP patients at the start of the disease, thus allowing a more prolonged course. The "three C rule" is applicable to virtually all nervous system disorders. It states that establishing rela-However, this cannot explain either the slower rate of progression observed in YOP patients in PET studies tionships between observed abnormalities is quite complex because they can be the true cause of the process, (9,55) or the relatively rare development of levodoparesistant symptoms in this subgroup of patients in spite but also a consequence of a subsequent process, or simply a reflection of compensatory mechanisms (cause, of a severe and early involvement of extranigral systems (see below). It should be recognized that the relationship consequence, or compensation). This rule emphasizes the role of compensation in neurological diseases. Usu-between the uptake of [ 18 F]dopa and parkinsonism is quite complex, particularly in early stages of the disease. ally, compensation takes place by a series of molecular changes included under the term neural plasticity. This
Other methodologies, such as raclopride displacement studies, may be more precise, but they are not widely may lead to positive, adaptive responses but also to maladaptive responses, which may be the basis of symptoms available at the present time. Compensatory mechanisms in PD have been recently reviewed (4). such as epilepsy or addiction (33) . There are two major ways by which neural plasticity may be expressed: func-Loss of Neurons During Ageing tional changes (such as increase in transmitter release, receptor regulation, and synaptic plasticity) and anatom-There is a reduction in the content of dopaminergic cells in the SNpc, which is age related. By using patho-ical modifications (in particular axonal regeneration, sprouting, synaptogenesis, and neurogenesis) (26) . Sev-logical and functional neuroimaging techniques it has been estimated that a loss of 0.5% of nigral neurons oc-eral data indicate that neural plasticity is under the control of genetics and age (14,44). Thus, ageing is associ-curs every year (18) . A concomitant decrease in the content of dopamine in the striatum accompanies ageing ated with a downregulation of the expression of genes related to synaptic plasticity, at least in the prefrontal (1,58). Also, the density of striatal dopamine receptors seems to diminish during the ageing process (1,58). Al-cortex (similar findings have been reported in the rat hippocampal region). Interestingly, the expression pro-though the distributions of neuronal loss within the SNpc and of loss of striatal dopamine terminals are of file of these genes in people younger than 40 and older than 71 is quite homogeneous (44) . However, consider-different topography to that observed in PD (18), it is likely that they contribute to some extent to the clinical able heterogeneity exists between 41 and 70 years (44) .
An interpretation of these findings could be that young outcome of PD, as well as to the appearance of certain subtle motoric disturbances observed in aged people. people have strong compensatory mechanisms whereas old individuals have weak ones, and middle age adults
Ageing-Related Pathologies are in between but with a high variability in the power of compensatory mechanisms. Extrapolating these data
The role of pathologies associated with ageing seems to be quite important and, in some cases, definitive. Loss to PD, it can be speculated that YOP patients, either with or without genetic mutations, have more "compe-or reduction of visual and auditory capabilities, osteoarticular disease, balance and equilibrium dysfunction, tent" compensatory mechanisms and subsequently less probability of experiencing levodopa-resistant symptoms, cerebrovascular lesions, and mild cognitive impairment with cerebral atrophy all are common in aged subjects but they are at high risk of developing aberrant compensation, which may result in the appearance of levodopa-and may contribute decisively to the evolution of older patients with PD (7,40). induced dyskinesias [see (42) and references therein). By contrast, old patients with a limited capacity for neu-In summary, the brain of YOP (independent of their genetic or sporadic origin) and older PD patients is quite ral plasticity do not develop dyskinesias but instead they are at high risk of suffering from symptoms related to different in terms of the general content of dopaminergic nerve endings and trophic support, compensatory power, progression of the disease, such as postural instability, cognitive disturbances, etc. For instance, some patients and associated pathologies. The negative effect of aging in the general outcome of PD has been suggested in with YOP due to mutations in the parkin gene may have severe impairment of striatal [ 18 F]dopa uptake when early and recent studies (7,40). Older PD patients might have increased motor disability, particularly axial distur-disabling (31) . Therefore, this idea may be true in general terms but several arguments need to be considered bances such as those related to gait, posture, and speech, because of more widespread subcortical involvement, (41) : including nondopaminergic structures such as the locus 1. Even if nondopaminergic nuclei are affected from the ceruleus, pedunculopontine nucleus, and nucleus basalis very beginning, their relevant clinical expression ocof Meynert. Thus, it is conceivable that all these differcurs very late (perhaps in the early phases this is limences may account for the different clinical outcome obited to subclinical or trivial symptoms). Indeed, some served after drug and surgical interventions. As a rule, symptoms related to dysfunction of these nuclei are it can be said that YOP patients will experience better improved by dopaminergic therapies in these early results than older patients. phases (i.e., depression). 2. Whereas PET and neuropathological studies of patients with parkin mutations show an involvement of THE ROLE OF NONDOPAMINERGIC some of these nuclei (locus ceruleus and nucleus bas-LESIONS IN THE OUTCOME OF PD alis of Meynert) (17, 30, 48, 65) , their outcome is quite Although the bulk of pathology in PD is concentrated benign, with a slower progression than patients with on dopaminergic systems, the degenerative process is idiopathic PD (35, 59) . not restricted to them (8,70). Indeed, PD is a multisys-3. Patients with tremor-dominant PD have a more betem disorder (8,70). Furthermore, it has been demonnign clinical course with little risk of developing levstrated that these nondopaminergic lesions occur quite odopa-resistant symptoms (71), although they have early, preceding the development of lesions in the SNpc an early and prominent involvement of the raphe nu-(8,70). It has been suggested that a stereotypic distribucleus, which is the origin of the most important serotion pattern of these lesions with a stereotypic progrestoninergic innervation of the brain (15). sion accounts for the stereotypic progression of symptoms and signs. The principal nondopaminergic lesions Furthermore, many questions remain unanswered (41) . Indeed, the results of a recent study question the involve the locus ceruleus, which has noradrenaline as the main neurotransmitter, the raphe nucleus, which uses Thus, the precise evolution of the pathological changes, and consequently the clinical outcome of patients, may systems also has to be considered.
Several attempts to correlate these abnormalities with be highly variable; the extent of pathological involvement in different neuronal populations is not fully known particular symptoms and signs of the disease have been made (20) . Hence, noradrenaline depletion has been re-and the rate of progression may differ in these nuclei. Do they progress in cascade, in parallel, or in a random lated to depression and postural abnormalities, serotonin deficiency to depression, and cortical acetylcholine de-manner? Are they due to a common pathogenic mechanism? Why do they appear just in the advanced stages? crease to cognitive abnormalities. However, to date, clinicopathological correlations have been poor (19) . Evi-
The study by Zarow et al. (70) showed that the duration of PD correlated with a greater neuronal loss in the dence supporting a role for these extradopaminergic lesions in the symptoms of PD have also been inten-SNpc rather than in the locus coeruleus, although the latter showed the greatest neuronal loss. This raises sively pursued, and perhaps the most clear evidence is the late appearance of symptoms and signs unresponsive more questions. Are nondopaminergic pathologies influenced by the same compensatory mechanisms involved to levodopa.
Some authors postulate that nondopaminergic involve-in the nigrostriatal system? Can antiparkinsonian drugs influence the evolution of pathology in these nuclei by ment plays a critical role in the outcome of PD, thus being the key factor for the success of any therapy (37, causing some sort of toxicity or by affecting negatively compensatory mechanisms? Will early application of 38). They claim that therapies acting only at the level of the dopaminergic nigrostriatal system and thus restricted cell replacement therapies modify this outcome by normalizing the functioning of the dopaminergic nigrostria-to replacement dopamine, whatever the mechanism, are condemned to failure (37, 38) . Indeed, the results of the tal pathway? At present it is impossible to determine the risk of a given patient developing this extradopaminer-Sidney multicenter study indicate that non-levodoparesponsive problems dominate at 15 years' disease dura-gic damage and the stage of disease at which such symptoms would arise. In recent years it has been claimed tion (31) . Depression, cognitive impairment, falls, and speech and swallowing problems are among the most that surgery could be more efficacious if applied early on in the disease course. However, until answers to these two hypothetical patients with a different rate of progression after a surgical intervention. The outcome of questions are found, the early use of surgery is not an absolute guarantee of remaining free of these late com-patient A is much better than the outcome of patient B despite the relative impact on the symptoms of the dis-plications.
ease being considerably bigger in the latter. If this is HYPOTHESIS: CENTRAL ROLE applied to the study of Olanow et al. (49), the group OF PD RATE OF PROGRESSION receiving grafts from four donors would experience a mean "relative" change of at least 12.2 points in the mo-Whereas it is clear that PD is a "more than dopaminergic disease" and that changes outside the nigrostriatal tor section of the UPDRS, which could be significant (Fig. 2) . system are present in early phases of the disease, their precise evolution and role in the outcome of current and DATA SUPPORTING THE HYPOTHESIS emerging therapies for the disease is not fully known Pathogenesis of "Runaway" and Off-Dyskinesias (41, 50) . Moreover, if the role of nondopaminergic le-After Transplantation sions is considered to be determinant, preoperative response to levodopa should be the best predictor of trans-In the Freed (21) and Olanow (49) studies, 15% and 56%, respectively, developed a particular type of dyski-plant outcome in the short term. This has been shown in one study (21, 22) but not in another (22, 49) .
nesia that was totally unexpected. Dyskinesias appeared after 6-12 months of the operation in Freed's study (21) It can be inferred from the analyzed data that the critical factor in the outcome of PD is not its multisystemic and a bit earlier in Olanow's study (49) (mean 5.1 months). Though they share some basic aspects, they also showed nature but the rate of progression of the disease, as well as the presence of additional lesions related to the ageing some peculiarities. Thus, in Freed's study (21) , during the double-blind part of the study, dyskinesias de-process. In other words, the power of compensatory mechanisms is critically involved in the clinical course creased, and only in the open-label, nonblinded extension part of the study did the dyskinesias appear in 15% because it is directly related to age and it determines the rate of progression, as well as the response to drugs. A of the patients grafted. The dyskinesias were mainly dystonic and often orofacial. They were present after comparative view of the results of recent studies using surgical approaches with respect to a "rate of progres-short (12 h) and longer drug withdrawal and persisted for days and weeks. In one case the dystonic dyskinesias sion index" gives support to this idea (Table 2) . This "rate of progression index" is the resultant score ob-disappeared after high dose L-dopa treatment was introduced and in two others, pallidal deep brain stimulation tained from dividing the score of the motor section of the UPDRS and the duration of PD. Such an index does (Gpi-DBS) was necessary. These are called "runaway" dyskinesias. In Olanow's study (49), dyskinesias were not exist and, therefore, it is necessarily arbitrary. Nevertheless, it serves to underline the existence of marked of different nature, observed in the "defined off" condition, at 12 h off medication. This was the per-protocol differences between studies in terms of the rate of progression of the disease (Table 2) . Thus, general conclu-assessment time point and reported accordingly. Fiftysix percent of the grafted patients displayed dyskinesias sions from clinical studies are difficult to draw, unless the role of disease progression is adequately addressed.
at this time point and under the conditions in the study (i.e., with the drug reductions limited to the protocol Figure 1 illustrates the differences in the evolution of type). If the antiparkinsonian medication was withdrawn for longer periods, up to 36 h in dyskinetic patients, all dyskinesia was quite rare in the experience of the Swed- ish group where dyskinesias were usually of mild or levodopa-induced dyskinesias that seem to be related to several factors such as disease severity, dose of levo-moderate severity and correlated with the previous existence of levodopa-induced dyskinesias (28) .
dopa, duration of treatment, and pulsatile stimulation of dopamine receptors. Age of onset of PD and genetic sus-The pathophysiology of these posttransplantation dyskinesias remains obscure. PD patients may experience ceptibility leading to abnormal synaptic plasticity might be of key importance [see (42) for a comprehensive re-dividual differences. Indeed, a potential interaction between age, clinical improvement, and development of view]. Initially, a link between dyskinesias and an overproduction of dopamine was reasonably suggested (21) . dyskinesias emerges from the study of Ma et al. (46) . Thus, off-medication dyskinesias and clinical benefit af-However, most clinical features of postgrafting dyskinesias (association with parkinsonism, phenomenology, fected mostly young people showing a significant clinical improvement and a great, but neither total nor homo-improvement after levodopa) indicate that they can be seen as the consequence of a situation of low dopamin-geneous, striatal reinnervation, leading to an uneven and uncontrolled stimulation of dopamine receptors by dopa-ergic tone. Indeed, PET studies show that the uptake of [ 18 F]dopa is improved after transplantation but is still mine released in an unregulated manner. In keeping with the central argument of this article, clinical improve-below normal values. Moreover, a reduction in the displacement of raclopride following amphetamine has not ment, dyskinesias, and striatal reinnervation were more marked in YOP patients because they have a slower pro-been found (Lindvall, XIII International Congress on Parkinson's Disease, Berlin, June, 2005). These data ex-gression of the disease and more powerful compensatory mechanisms (both adaptive and maladaptive) than older clude the existence of a general and homogeneous overproduction of dopamine by the graft. However, a non-PD patients. This is also supported by the basal disease severity, which was considerably less in patients with a homogeneous, local overproduction of dopamine by surviving cells cannot be ruled out by using currently strong clinical response (improvement with dyskinesias) and striatal reinnervation. In addition, prior animal stud-available PET technologies. Ma et al. analyzed the outcome of patients with and without dyskinesias in the ies have shown that graft survival is considerably reduced in aged animals (12,60), suggesting that YOP pa-Freed study (46) . The sample size was very small but there are several interesting points in this analysis. Base-tients could have greater cell survival than aged PD patients. In other words, the younger the patient, the line severity of disease as assessed by the UPDRS III was different: 30.7 and 44 in the dyskinetic and nondys-slower the progression of the disease, the greater the survival of implanted cells, the greater the clinical im-kinetic groups, respectively. Also, dyskinesias affected those patients with the greater clinical improvement provement, and the higher the risk of developing dyskinesias, which adopts the clinical and chronological pat-(63.6% improvement at 2 years with an UPDRS III scoring 30.7 at baseline and 11.3 2 years latter). Addition-tern of biphasic dyskinesias because dopaminergic tone is still below normal levels. ally, serial [ 18 F]dopa PET scans performed with 2 years of the occurrence of a difference showed a greater in-Furthermore, alternative explanations cannot be ruled out and "runaway" and off-dyskinesias might be consid-crease in the uptake of [ 18 F]dopa in patients with dyskinesias (73.5% vs. 26.8%) (46) . This small study sug-ered as an unrelated phenomenon, linked exclusively to the pattern of reinnervation rather than to the total gests that dyskinesias appeared in YOP patients with moderate disease severity and showing a great improve-amount of surviving tissue. In this setting, it is worth mentioning the potential role of the ventral striatum, ment in clinical rating scales and [ 18 F]dopa PET, indicating a greater survival of implanted cells relative to pa-both in clinical improvement and in the appearance of dyskinesias, as has been suggested in PET studies tients not experiencing dyskinesias.
By contrast, most of these relationships were ex-[ (46, 54) , Lindvall XIII International Congress on Parkinson's Disease, Berlin, June, 2005]. Hence, the five cluded by Olanow and colleagues (49). These authors did not find significant differences either in the UPDRS patients who developed dyskinesias in Ma's study (46) had a higher [ 18 F]dopa uptake in the putamen than the or in [ 18 F]dopa PET uptake results between patients with and without dyskinesias. Unexpectedly, patients with patients who did not develop these symptoms. In particular, the difference in [ 18 F]dopa uptake was observed in lower requirements of levodopa were more prone to develop dyskinesias. Also these patients showed a higher the posterodorsal putamen, which is the most affected region in PD and is the usual target for neural transplan-magnitude of response to levodopa (difference between UPDRS motor scores in the off and in the on) than pa-tation, and in the ventral putamen, which is relatively spared in most cases of PD. The disparity in [ 18 F]dopa tients without dyskinesias. Importantly, dyskinesias appeared after stopping immunosuppressive treatment. uptake in the ventral putamen was most prominent when the group of dyskinetic patients was compared with the They concluded that off-medication dyskinesias could be related to graft variability, nonuniform striatal rein-nondyskinetic patients with greatest clinical response to transplantation. In this setting, animal studies are quite nervation, partial immune rejection, and altered synapse formation causing regional inhomogeneities with pulsa-interesting because previous results are conflicting (39, 61) . Whereas Lee et al. found a reduction in levodopa-tile stimulation of dopamine receptors (49). This is a quite plausible explanation but additional factors should induced dyskinesias after transplantation of embryonic dopaminergic neurons to parkinsonian rats (39), Steece-be taken into account in order to understand the interin- (61) . Interestingly, unlikely. Indeed, no correlation between the extent of striatal [ 18 F]dopa uptake decline and severity of parkin-this last group has recently provided further insight on these enigmatic dyskinesias by comparing the behav-sonism could be found in parkin+ patients, suggesting the existence of extraordinarily powerful compensatory ioral and neurochemical consequences of dopamine reinnervation restricted to a focal region of the striatum to mechanisms. Moreover, it has been previously reported by using PET techniques that the rate of progression of innervation encompassing the majority of the striatum by distributing the same number of cells into single lo-the nigrostriatal dopaminergic dysfunction is actually significantly slower in parkin+ patients compared to pa-cus or multiple locations (47) . Both the single-site and widespread grafts reduced pregraft dyskinesias. How-tients with PD but an older age (35) . In this study serial [ 18 F]dopa PET was used to measure over a 10-year pe-ever, single-site, "hot-spot" graft recipients developed a robust, novel forelimb-facial stereotypy and upregulated riod the rate of loss of dopaminergic function in clinically affected members of a kindred with parkin disease the expression of genes related to dyskinesias in the ventrolateral striatum, an area associated with movements (35 (45, 51) . Parkin+ YOP patients have a relatively high show a similar slow evolution (36,51). A comparable disparity between moderate clinical impairment and se-frequency of psychiatric disturbances. This suggests that there is a more diffuse damage to the brain (including vere nigrostriatal dopaminergic dysfunction has been reported for PINK1 (PARK6) and DJ-1 (PARK7) patients, the limbic system) as has been recently demonstrated in a few pathological observations, in which denervation in both recessive forms of YOP (13,34,64). Thus, the discrepancy may simply be a reflection of the strength of the locus ceruleus, nucleus basalis of Meynert, substantia nigra reticulata, parts of the spinocerebellar system, the compensatory mechanisms in parkin+, DJ-1+, and PINK1+ patients (likely in YOP patients as a distinct and the amygdalo-hippocampal region was found (17, 30, 48, 65) . group), which may also be responsible for the earlier development of levodopa-induced dyskinesias (42) . PET findings in the largest study conducted so far seem to corroborate these pathological data (59). A se-CONCLUDING REMARKS vere reduction of caudate and putaminal [ 18 F]dopa uptake, together with reductions in the [ 18 F]dopa uptake in Surgical (and presumably pharmacological) treatments will work much better and for longer periods of time midbrain areas and in cortical areas, was encountered (59). The disturbance of the striatal uptake is not very in YOP due to the slow disease progression and later involvement of nondopaminergic structures, although different to the one observed in parkin− YOP and PD patients. The decline in midbrain uptake of the radio-dyskinesias may be a problem in this population. Thus, the rate of progression of PD should be thoroughly ana-tracer suggests an involvement of catecholaminergic and serotoninergic nuclei located in this area (i.e., serotonin-lyzed in the selection process of surgical candidates, together with the presence of additional cerebral lesions. ergic raphe nucleus and locus ceruleus). This pattern has also been observed in advanced cases of PD and indi-In addition to age of onset, age at time of surgery is also crucial. In order to be maximally effective, any surgical cates a more widespread pathologic process.
The clinical relevance of these findings is not clearly procedure should be performed in the absence of relevant additional brain pathologies (vascular lesions and understood. These imaging and pathological studies could suggest that parkin+ patients have a more devas-cortical atrophy). This hypothesis does not imply that older patients should not be considered as candidates for tating and widespread pathological degenerative process, which is expressed as a more severe parkinsonian surgery programs provided the rate of progression is slow and they are free of additional pathologies. syndrome with a very rapid evolution, but this seems Furthermore, transplantation should ideally be carried dures and multiple implantation sites based on detailed imaging of the denervation patterns in the individual pa-out when dysfunctional compensatory mechanisms are still reversible, a possibility more remote with the pas-tient. I fully agree with this conclusion, but I believe that an alternative conclusion is also possible: rate of sage of time. Furthermore, this could influence the rate of progression of PD and provide additional clinical progression of PD might be determinant in the final outcome. benefit to that purely derived from the increase in the number of dopaminergic terminals. Could this also be REFERENCES necessary for DBS? There is no support for this notion at the present time. volved in neural plasticity. It is tempting to speculate
